Background Prospective studies correlating pharmacokinetic/pharmacodynamic (PK/PD)
indices to clinical responses are urgently needed. This study aimed to find clinically relevant …

Background. New first-line drug regimens for treatment of tuberculosis (TB) are in clinical
trials: emergence of resistance is a key concern. Because population-level data on …

The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …

Drug resistant tuberculosis contributes significantly to the global burden of antimicrobial
resistance, often consuming a large proportion of the healthcare budget and associated …

One problem associated with regimen-based development of antituberculosis (anti-TB)
drugs is the difficulty of a systematic and thorough in vivo evaluation of the large number of …

Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid,
rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to …

Even if major improvements in therapeutic regimens and treatment outcomes have been
progressively achieved, tuberculosis (TB) remains the leading cause of death from a single …

Due to its high early bactericidal activity, isoniazid (INH) plays an essential role in
tuberculosis treatment. Genetic polymorphisms of N-acetyltransferase type 2 (NAT2) cause a …

Since standardized rifampin‐based first‐line regimens and fluoroquinolone‐based second‐
line regimens were used to treat tuberculosis (TB), unfortunately without timely modification …

Tuberculosis (TB) drug development has made substantial progress in the past decade.
There are currently at least ten drugs being evaluated in clinical trials. Some belong to …